0-4℃ for short term (days to weeks), or -20℃ for long term (months).
ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | 346.00 | |
10 mg | In stock | 541.00 | |
25 mg | In stock | 971.00 | |
50 mg | In stock | 1616.00 | |
100 mg | In stock | 2202.00 | |
200 mg | In stock | inquiry | |
500 mg | In stock | inquiry | |
1 mL * 10 mM (in DMSO) | In stock | 272.00 |
Description | ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML. |
Targets&IC50 | DHODH, |
In vivo | ASLAN003 substantially reduces leukemic burden and prolongs survival in acute myeloid leukemia xenograft mice and acute myeloid leukemia patient-derived xenograft models. Notably, the drug has no evident effect on normal hematopoietic cells and exhibits excellent safety profiles in mice, even after a prolonged period of administration. ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients[2]. |
Molecular Weight | 356.32 |
Formula | C19H14F2N2O3 |
CAS No. | 1035688-66-4 |
0-4℃ for short term (days to weeks), or -20℃ for long term (months).
DMSO: 120 mg/mL (336.78 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.